An open-label randomized, controlled trial of the effect of lopinavir and ritonavir, lopinavir and ritonavir plus interferon-β-1a, and hydroxychloroquine in hospitalized patients with COVID-19: final results

We published in the December 2021 issue of Clinical Microbiology and Infection the preliminary results of the DisCoVeRy trial regarding the efficacy of lopinavir/ritonavir, lopinavir/ritonavir plus interferon (IFN)-β-1a, and hydroxychloroquine in hospitalized patients with COVID-19 [1]. These three experimental repurposed treatments did not show clinical or virological benefit in the studied population. Of note, the number of patients included was low as inclusion in those arms of the trial was prematurely stopped by the data safety monitoring board (DSMB).